Sanford Burnham
  • Sanford Burnham
  • Twitter
  • Facebook
  • Youtube
  • Navigate Sanford-Burnham
    • Main Site
    • Our Mission
    • Research
    • Talent
    • Technology
    • Training & Education
    • Our Supporters
    • News

Beaker

Sanford-Burnham Science Blog

Subscribe

Targeting prostate tumors with nanoworms

by Heather Buschman, Ph.D. on July 6, 2010 at 4:29 pm | 6 Comments

One way to inhibit a tumor’s growth is to choke off its blood supply. The trick is to create a clot that specifically blocks flow to the tumor without harming other parts of the body. To accomplish this, a research team led by Dr. Erkki Ruoslahti, distinguished professor at Sanford-Burnham, coated nanoparticles with two different homing signals that specifically direct them to proteins on tumor blood vessels. One signal was generated by a string of just five amino acids (the molecular subunits that make up a protein), while the other consisted of six amino acids. These two types of targeted nanoparticles worked cooperatively to induce blood clots, and an elongated version of these particles, called “nanoworms,” did an even better job of it. As the nanoworms induced clotting, more and more binding sites appeared, attracting more nanoworms and further enhancing the blockage.

In a study published June 29, 2010 in the journal Blood, the researchers used the targeted nanoworms to treat a mouse model of human prostate cancer. The nanoworms triggered widespread clotting in the prostate tumor vessels, but left normal tissues alone. As a result, the cancer cells starved and the tumors shrank.

“The nanoparticle combination we used gives a dramatic reduction in tumor growth, and there is no drug involved,” explained Dr. Ruoslahti. “Next, we’ll add a drug to one or both of the nanoparticles to further boost the efficacy, hopefully to a point where we can cure the mice of their tumors.”

Tags: Center for Nanomedicine, Erkki Ruoslahti, research publications, Santa Barbara, tumor microenvironment

Post a Comment Cancel reply

* All fields are required

CAPTCHA Image
Refresh Image

*

6 Comments

  1. Constance Moni says:
    February 25, 2012 at 4:04 am

    technology just keeps getting better but weither or not it will be 100% effective is a question that is to be answered…#random

    Reply
  2. HZ Malina says:
    November 25, 2011 at 1:55 am

    “As the nanoworms induced clotting, more and more binding sites appeared, attracting more nanoworms and further enhancing the blockage”.
    Would they do the cancers cure and cause the death by general thrombosis (statistic for cancers would be better)?

    Reply
  3. Lyle LaRosh says:
    July 7, 2010 at 7:19 pm

    Can you please explain the efficacy of your worms as compared to Avastin. As we all know, Avastin stops angiogenisis. How does this differ from your research. Also, how do you relate to Provenge?

    Reply
    • Josh Baxt says:
      July 8, 2010 at 7:31 am

      This research is at the very earliest stages, so there has been no comparative efficacy testing yet. However, Dr. Ruoslahti’s research highlights a new approach against prostate cancer that may have great potential. Much more work to be done.

      Reply

Search

Find more information

  • About Beaker
  • Contact us
  • Donate

Please take a quick survey

Which of these items describes you?

Select all that apply. (Question 1 of 5)

Categories

  • Basic Research
  • Cancer
    • Apoptosis & Cell Death Research
    • Signal Transduction
    • Tumor Development
    • Tumor Microenvironment
  • Children's Health
    • Genetic Diseases
    • Muscle Development & Regeneration
    • RNA Biology
  • Diabetes & Obesity
    • Cardiovascular Pathobiology
    • Metabolic Signaling & Disease
  • Drug Discovery
  • Events
  • Graduate School of Biomedical Sciences
  • Grants
  • Infectious & Inflammatory Diseases
    • Bioinformatics & Systems Biology
    • Infectious Diseases
    • Inflammatory Diseases
  • Nanomedicine
  • Neuroscience, Aging, & Stem Cells
    • Degenerative Diseases
    • Development & Aging
    • Stem Cells
  • Other
  • People
  • Sanford-Burnham Supporters
  • Translational Medicine

Search by Keyword

CCRA CIRM collaboration commitment communication community Daniel Kelly Erkki Ruoslahti Evan Snyder events Florida Hospital Fred Levine Genetic Disease Program Guy Salvesen Hudson Freeze John Reed Kristiina Vuori La Jolla Lake Nona Metabolic Signaling metabolism NIH Orlando personalized medicine Prebys Center press proteins Rare Diseases Rare disease symposium research publications Robert Wechsler-Reya Santa Barbara Sara Courtneidge Sheila Collins Stem Cells Steven Smith Stuart Lipton T. Denny Sanford technology Translational Research Institute tumor microenvironment Tumor Microenvironment Program Video Yu Yamaguchi Ze'ev Ronai

© Sanford-Burnham Medical Research Institute. All rights reserved.

Get Cloud PHP Hosting on CatN